SON-1400 / Sonnet BioTherap - LARVOL DELTA

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates (GlobeNewswire) - "Sonnet BioTherapeutics Holdings, Inc...announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,134,635 entitled 'Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same,' covering two of its novel drug candidates, SON-1411 (IL-18BPR-FHAB-IL12) and SON-1400 (IL-18BPR-FHAB), each containing a modified version of recombinant human interleukin-18 (IL-18BPR = Binding Protein Resistant). The patent carries a term effective until June 2044."

Patent • Oncology